Comparison of Caffeine and d-amphetamine in Cocaine-Dependent Subjects: Differential Outcomes on Subjective and Cardiovascular Effects, Reward Learning, and Salivary Paraxanthine

Due to indirect modulation of dopamine transmission, adenosine receptor antagonists may be useful in either treating cocaine use or improving disrupted cognitive-behavioral functions associated with chronic cocaine use. To compare and contrast the stimulant effects of adenosine antagonism to direct...

Full description

Saved in:
Bibliographic Details
Published inJournal of addiction research & therapy Vol. 5; no. 2; p. 176
Main Author Lane, Scott D
Format Journal Article
LanguageEnglish
Published United States 2014
Subjects
Online AccessGet full text
ISSN2155-6105
2155-6105
DOI10.4172/2155-6105.1000176

Cover

Abstract Due to indirect modulation of dopamine transmission, adenosine receptor antagonists may be useful in either treating cocaine use or improving disrupted cognitive-behavioral functions associated with chronic cocaine use. To compare and contrast the stimulant effects of adenosine antagonism to direct dopamine stimulation, we administered 150 mg and 300 mg caffeine, 20 mg amphetamine, and placebo to cocaine-dependent vs. healthy control subjects, matched on moderate caffeine use. Data were obtained on measures of cardiovascular effects, subjective drug effects (ARCI, VAS, DEQ), and a probabilistic reward-learning task sensitive to dopamine modulation. Levels of salivary caffeine and the primary caffeine metabolite paraxanthine were obtained on placebo and caffeine dosing days. Cardiovascular results revealed main effects of dose for diastolic blood pressure and heart rate; follow up tests showed that controls were most sensitive to 300 mg caffeine and 20 mg amphetamine; cocaine-dependent subjects were sensitive only to 300 mg caffeine. Subjective effects results revealed dose × time and dose × group interactions on the ARCI A, ARCI LSD, and VAS 'elated' scales; follow up tests did not show systematic differences between groups with regard to caffeine or d-amphetamine. Large between-group differences in salivary paraxanthine (but not salivary caffeine) levels were obtained under both caffeine doses. The cocaine-dependent group expressed significantly higher paraxanthine levels than controls under 150 mg and 3-4 fold greater levels under 300 mg at 90 min and 150 min post caffeine dose. However, these differences also covaried with cigarette smoking status (not balanced between groups), and nicotine smoking is known to alter caffeine/paraxanthine metabolism via cytochrome P450 enzymes. These preliminary data raise the possibility that adenosine antagonists may affect cocaine-dependent and non-dependent subjects differently. In conjunction with previous preclinical and human studies, the data suggest that adenosine modulating drugs may have value in the treatment of stimulant use disorders.
AbstractList Due to indirect modulation of dopamine transmission, adenosine receptor antagonists may be useful in either treating cocaine use or improving disrupted cognitive-behavioral functions associated with chronic cocaine use. To compare and contrast the stimulant effects of adenosine antagonism to direct dopamine stimulation, we administered 150 mg and 300 mg caffeine, 20 mg amphetamine, and placebo to cocaine-dependent vs. healthy control subjects, matched on moderate caffeine use. Data were obtained on measures of cardiovascular effects, subjective drug effects (ARCI, VAS, DEQ), and a probabilistic reward-learning task sensitive to dopamine modulation. Levels of salivary caffeine and the primary caffeine metabolite paraxanthine were obtained on placebo and caffeine dosing days. Cardiovascular results revealed main effects of dose for diastolic blood pressure and heart rate; follow up tests showed that controls were most sensitive to 300 mg caffeine and 20 mg amphetamine; cocaine-dependent subjects were sensitive only to 300 mg caffeine. Subjective effects results revealed dose × time and dose × group interactions on the ARCI A, ARCI LSD, and VAS 'elated' scales; follow up tests did not show systematic differences between groups with regard to caffeine or d-amphetamine. Large between-group differences in salivary paraxanthine (but not salivary caffeine) levels were obtained under both caffeine doses. The cocaine-dependent group expressed significantly higher paraxanthine levels than controls under 150 mg and 3-4 fold greater levels under 300 mg at 90 min and 150 min post caffeine dose. However, these differences also covaried with cigarette smoking status (not balanced between groups), and nicotine smoking is known to alter caffeine/paraxanthine metabolism via cytochrome P450 enzymes. These preliminary data raise the possibility that adenosine antagonists may affect cocaine-dependent and non-dependent subjects differently. In conjunction with previous preclinical and human studies, the data suggest that adenosine modulating drugs may have value in the treatment of stimulant use disorders.Due to indirect modulation of dopamine transmission, adenosine receptor antagonists may be useful in either treating cocaine use or improving disrupted cognitive-behavioral functions associated with chronic cocaine use. To compare and contrast the stimulant effects of adenosine antagonism to direct dopamine stimulation, we administered 150 mg and 300 mg caffeine, 20 mg amphetamine, and placebo to cocaine-dependent vs. healthy control subjects, matched on moderate caffeine use. Data were obtained on measures of cardiovascular effects, subjective drug effects (ARCI, VAS, DEQ), and a probabilistic reward-learning task sensitive to dopamine modulation. Levels of salivary caffeine and the primary caffeine metabolite paraxanthine were obtained on placebo and caffeine dosing days. Cardiovascular results revealed main effects of dose for diastolic blood pressure and heart rate; follow up tests showed that controls were most sensitive to 300 mg caffeine and 20 mg amphetamine; cocaine-dependent subjects were sensitive only to 300 mg caffeine. Subjective effects results revealed dose × time and dose × group interactions on the ARCI A, ARCI LSD, and VAS 'elated' scales; follow up tests did not show systematic differences between groups with regard to caffeine or d-amphetamine. Large between-group differences in salivary paraxanthine (but not salivary caffeine) levels were obtained under both caffeine doses. The cocaine-dependent group expressed significantly higher paraxanthine levels than controls under 150 mg and 3-4 fold greater levels under 300 mg at 90 min and 150 min post caffeine dose. However, these differences also covaried with cigarette smoking status (not balanced between groups), and nicotine smoking is known to alter caffeine/paraxanthine metabolism via cytochrome P450 enzymes. These preliminary data raise the possibility that adenosine antagonists may affect cocaine-dependent and non-dependent subjects differently. In conjunction with previous preclinical and human studies, the data suggest that adenosine modulating drugs may have value in the treatment of stimulant use disorders.
Due to indirect modulation of dopamine transmission, adenosine receptor antagonists may be useful in either treating cocaine use or improving disrupted cognitive-behavioral functions associated with chronic cocaine use. To compare and contrast the stimulant effects of adenosine antagonism to direct dopamine stimulation, we administered 150 mg and 300 mg caffeine, 20 mg amphetamine, and placebo to cocaine-dependent vs. healthy control subjects, matched on moderate caffeine use. Data were obtained on measures of cardiovascular effects, subjective drug effects (ARCI, VAS, DEQ), and a probabilistic reward-learning task sensitive to dopamine modulation. Levels of salivary caffeine and the primary caffeine metabolite paraxanthine were obtained on placebo and caffeine dosing days. Cardiovascular results revealed main effects of dose for diastolic blood pressure and heart rate; follow up tests showed that controls were most sensitive to 300 mg caffeine and 20 mg amphetamine; cocaine-dependent subjects were sensitive only to 300 mg caffeine. Subjective effects results revealed dose × time and dose × group interactions on the ARCI A, ARCI LSD, and VAS ‘elated’ scales; follow up tests did not show systematic differences between groups with regard to caffeine or d-amphetamine. Large between-group differences in salivary paraxanthine (but not salivary caffeine) levels were obtained under both caffeine doses. The cocaine-dependent group expressed significantly higher paraxanthine levels than controls under 150 mg and 3–4 fold greater levels under 300 mg at 90 min and 150 min post caffeine dose. However, these differences also covaried with cigarette smoking status (not balanced between groups), and nicotine smoking is known to alter caffeine/paraxanthine metabolism via cytochrome P450 enzymes. These preliminary data raise the possibility that adenosine antagonists may affect cocaine-dependent and non-dependent subjects differently. In conjunction with previous preclinical and human studies, the data suggest that adenosine modulating drugs may have value in the treatment of stimulant use disorders.
Author Lane, Scott D
AuthorAffiliation 2 Center for Human Toxicology, University of Utah, Salt Lake City, UT, USA
1 Center for Neurobehavioral Research on Addictions, Department of Psychiatry & Behavioral Sciences, University of Texas Health Science Center – Houston, Houston, TX USA
3 Integrative Neurobiology, Intramural Research Program, National Institute on Drug Abuse, Baltimore, MD, USA
4 Division on Addictions, Department of Psychiatry, Virginia Commonwealth University, Richmond, VA, USA
AuthorAffiliation_xml – name: 4 Division on Addictions, Department of Psychiatry, Virginia Commonwealth University, Richmond, VA, USA
– name: 2 Center for Human Toxicology, University of Utah, Salt Lake City, UT, USA
– name: 1 Center for Neurobehavioral Research on Addictions, Department of Psychiatry & Behavioral Sciences, University of Texas Health Science Center – Houston, Houston, TX USA
– name: 3 Integrative Neurobiology, Intramural Research Program, National Institute on Drug Abuse, Baltimore, MD, USA
Author_xml – sequence: 1
  givenname: Scott D
  surname: Lane
  fullname: Lane, Scott D
BackLink https://www.ncbi.nlm.nih.gov/pubmed/25414797$$D View this record in MEDLINE/PubMed
BookMark eNqFUc1u1DAQtlARLaUPwAX5yKEpdmInLgekKi0_0kpFFM7WxJl0XSV2sJMtfS2eEIddSuEAJ49mvh_PN0_JnvMOCXnO2YngVf4q51JmJWfyhDPGeFU-Igf3vb0H9T45ivEmYVhxqk5z_oTs51JwUZ1WB-R77YcRgo3eUd_RGroOrUMKrqVtBsO4xgmGpWMdrb2BVGbnOKJr0U30am5u0EzxNT23iRlSz0JPL-fJ-AEjTao7iN1sRWsIrfUbiGbuIdCLxEr8Y_oJb9OErhCCs-76-Cf4Cnq7gXBHP0KAb-CmdbJ_Rh530Ec82r2H5Mvbi8_1-2x1-e5DfbbKTC5EmQklsGrBlDkI0TGlJMjCIErOedNI1SilKjC8ZF2jRCtkx0EAFK3Ii4JzVRySfKs7uxHubqHv9RjskL6jOdPLDfSSsV4y1rsbJNKbLWmcmwFbkwIJ8Jvoweo_J86u9bXf6OQqq3JxfbkTCP7rjHHSg40G-x4c-jlqrvKyZIUqRYK-eOh1b_LruglQbQEm-BgDdtrYCSbrF2vb_3MN_hfz_6v_AIwxyy0
CitedBy_id crossref_primary_10_1016_j_drugalcdep_2016_06_022
crossref_primary_10_1002_hup_2545
crossref_primary_10_3389_fphar_2017_00985
crossref_primary_10_1038_npp_2014_322
crossref_primary_10_1016_j_ijpsycho_2021_07_625
crossref_primary_10_1016_j_drugalcdep_2016_04_013
crossref_primary_10_3389_fphar_2021_752826
crossref_primary_10_1111_add_15242
ContentType Journal Article
Copyright 2014 Lane SD, et al. 2014
Copyright_xml – notice: 2014 Lane SD, et al. 2014
DBID AAYXX
CITATION
NPM
7X8
5PM
ADTOC
UNPAY
DOI 10.4172/2155-6105.1000176
DatabaseName CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
Unpaywall for CDI: Periodical Content
Unpaywall
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

PubMed
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: UNPAY
  name: Unpaywall
  url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
EISSN 2155-6105
ExternalDocumentID 10.4172/2155-6105.1000176
PMC4235768
25414797
10_4172_2155_6105_1000176
Genre Journal Article
GrantInformation_xml – fundername: NIDA NIH HHS
  grantid: P50 DA009262
GroupedDBID 8TZ
AAKDD
AAYXX
ALMA_UNASSIGNED_HOLDINGS
CITATION
EBS
EJD
KQ8
NPM
7X8
5PM
ADTOC
UNPAY
ID FETCH-LOGICAL-c2446-484e7dac62a44f0885a53cee5111bb58b8887ac160fb84d45f1a4aa3d42331183
IEDL.DBID UNPAY
ISSN 2155-6105
IngestDate Wed Oct 29 12:17:27 EDT 2025
Thu Aug 21 14:00:10 EDT 2025
Thu Oct 02 11:32:45 EDT 2025
Mon Jul 21 05:49:54 EDT 2025
Tue Jul 01 02:34:59 EDT 2025
Thu Apr 24 23:09:20 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed false
IsScholarly true
Issue 2
Keywords Adenosine A1/A2 receptor
Cocaine dependence
Human
Reward learning
Cardiovascular effects
Subjective effects
Paraxanthine
d-amphetamine
Caffeine
Language English
License This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
cc-by
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c2446-484e7dac62a44f0885a53cee5111bb58b8887ac160fb84d45f1a4aa3d42331183
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://proxy.k.utb.cz/login?url=https://doi.org/10.4172/2155-6105.1000176
PMID 25414797
PQID 1826603864
PQPubID 23479
ParticipantIDs unpaywall_primary_10_4172_2155_6105_1000176
pubmedcentral_primary_oai_pubmedcentral_nih_gov_4235768
proquest_miscellaneous_1826603864
pubmed_primary_25414797
crossref_citationtrail_10_4172_2155_6105_1000176
crossref_primary_10_4172_2155_6105_1000176
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2014-00-00
20140101
PublicationDateYYYYMMDD 2014-01-01
PublicationDate_xml – year: 2014
  text: 2014-00-00
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Journal of addiction research & therapy
PublicationTitleAlternate J Addict Res Ther
PublicationYear 2014
References 11325419 - Pharmacol Biochem Behav. 2001 Mar;68(3):611-27
3663788 - Biol Psychiatry. 1987 Nov;22(11):1357-68
16237380 - Neuropsychopharmacology. 2006 May;31(5):1064-74
15022032 - Eur J Clin Pharmacol. 2004 Apr;60(2):103-7
9832935 - Behav Pharmacol. 1998 May;9(3):207-17
10780285 - Behav Pharmacol. 1999 Dec;10(8):707-16
21264319 - PLoS One. 2011 Jan 11;6(1):e16088
17913879 - Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16311-6
20021728 - Br J Math Stat Psychol. 2010 May;63(Pt 2):379-93
4456431 - Psychol Med. 1974 Nov;4(4):364-73
22735770 - Neuropharmacology. 2013 Jan;64:452-63
21156654 - Circulation. 2010 Dec 14;122(24):2558-69
22905331 - J Addict Res Ther. 2012 Mar 28;S1:null
17561238 - Pharmacol Biochem Behav. 2007 Jun-Jul;87(2):289-96
22500978 - Addict Biol. 2013 May;18(3):455-66
2512494 - NIDA Res Monogr. 1989;92:211-30
22906516 - Biol Psychiatry. 2013 Feb 1;73(3):219-24
15006288 - Behav Cogn Neurosci Rev. 2003 Dec;2(4):227-60
17164816 - Neuropsychopharmacology. 2007 Jul;32(7):1583-99
21123574 - J Neurosci. 2010 Dec 1;30(48):16284-92
5554941 - Clin Pharmacol Ther. 1971 Mar-Apr;12(2):245-58
18306243 - Ann Neurol. 2008 Mar;63(3):295-302
20201847 - Ann N Y Acad Sci. 2010 Feb;1187:76-100
22654774 - Front Psychiatry. 2012 May 28;3:44
11557168 - Neuropsychopharmacology. 2001 Oct;25(4):548-54
11927167 - Neuropsychopharmacology. 2002 Apr;26(4):422-30
12213517 - Pharmacol Biochem Behav. 2002 Nov;73(4):729-41
23736314 - Neuropsychopharmacology. 2013 Nov;38(12):2427-38
10049999 - Pharmacol Rev. 1999 Mar;51(1):83-133
22149529 - Expert Rev Cardiovasc Ther. 2012 Jan;10(1):105-27
21827488 - J Pharm Pharmacol. 2011 Sep;63(9):1161-8
22300101 - Future Med Chem. 2012 Feb;4(2):245-65
15019424 - Neurosci Biobehav Rev. 2004 Jan;27(8):739-49
7862879 - Psychopharmacology (Berl). 1994 Jun;115(1-2):1-8
21731559 - Front Neuroanat. 2011 Jun 17;5:36
9234049 - Exp Clin Psychopharmacol. 1997 May;5(2):130-6
22750066 - Pharmacol Biochem Behav. 2012 Oct;102(4):526-31
9476695 - Drug Alcohol Depend. 1997 Dec;49(1):17-24
15550951 - Nat Rev Neurosci. 2004 Dec;5(12):963-70
20307491 - Biochem Biophys Res Commun. 2010 Apr 16;394(4):988-92
15528409 - Science. 2004 Dec 10;306(5703):1940-3
16128905 - Basic Clin Pharmacol Toxicol. 2005 Sep;97(3):125-34
660527 - J Pharmacol Exp Ther. 1978 Jun;205(3):525-35
1786488 - Br J Addict. 1991 Dec;86(12):1563-70
19211970 - Pharmacol Rep. 2008 Nov-Dec;60(6):789-97
1595423 - Addict Behav. 1992;17(1):27-33
3297472 - Clin Sci (Lond). 1987 Jun;72(6):749-56
12766934 - Hum Psychopharmacol. 2003 Jun;18(4):291-9
2512504 - NIDA Res Monogr. 1989;92:73-100
21464202 - Nicotine Tob Res. 2011 Jun;13(6):401-11
2302795 - Clin Chem. 1990 Feb;36(2):391
23261866 - Neuropharmacology. 2013 Apr;67:476-84
17962524 - Science. 2007 Nov 23;318(5854):1309-12
20166094 - Cochrane Database Syst Rev. 2010 Feb 17;(2):CD007380
12927652 - Drug Alcohol Depend. 2003 Aug 20;71(2):143-52
21072503 - Psychopharmacology (Berl). 2011 Apr;214(3):665-74
11160635 - J Pharmacol Exp Ther. 2001 Feb;296(2):486-94
12325108 - Stat Med. 2002 Oct 15;21(19):2917-30
18428072 - Am J Drug Alcohol Abuse. 2008;34(3):293-305
1602393 - J Pharmacol Exp Ther. 1992 Jun;261(3):885-94
24324449 - Front Psychol. 2013 Nov 26;4:863
7714788 - J Pharmacol Exp Ther. 1995 Apr;273(1):351-8
19058926 - Drug Alcohol Depend. 2009 Apr 1;101(1-2):34-41
8834422 - J Clin Psychopharmacol. 1996 Feb;16(1):72-6
15582920 - J Psychopharmacol. 2004 Dec;18(4):534-43
16972106 - Psychopharmacology (Berl). 2006 Nov;189(1):17-25
20182056 - J Alzheimers Dis. 2010;20 Suppl 1:S35-49
17981720 - Front Biosci. 2008 Jan 01;13:2391-9
18164144 - Drug Alcohol Depend. 2008 Apr 1;94(1-3):142-50
References_xml – reference: 4456431 - Psychol Med. 1974 Nov;4(4):364-73
– reference: 7714788 - J Pharmacol Exp Ther. 1995 Apr;273(1):351-8
– reference: 23736314 - Neuropsychopharmacology. 2013 Nov;38(12):2427-38
– reference: 22750066 - Pharmacol Biochem Behav. 2012 Oct;102(4):526-31
– reference: 2512494 - NIDA Res Monogr. 1989;92:211-30
– reference: 660527 - J Pharmacol Exp Ther. 1978 Jun;205(3):525-35
– reference: 22500978 - Addict Biol. 2013 May;18(3):455-66
– reference: 11160635 - J Pharmacol Exp Ther. 2001 Feb;296(2):486-94
– reference: 15550951 - Nat Rev Neurosci. 2004 Dec;5(12):963-70
– reference: 19211970 - Pharmacol Rep. 2008 Nov-Dec;60(6):789-97
– reference: 17164816 - Neuropsychopharmacology. 2007 Jul;32(7):1583-99
– reference: 21827488 - J Pharm Pharmacol. 2011 Sep;63(9):1161-8
– reference: 21156654 - Circulation. 2010 Dec 14;122(24):2558-69
– reference: 16128905 - Basic Clin Pharmacol Toxicol. 2005 Sep;97(3):125-34
– reference: 11557168 - Neuropsychopharmacology. 2001 Oct;25(4):548-54
– reference: 3297472 - Clin Sci (Lond). 1987 Jun;72(6):749-56
– reference: 15006288 - Behav Cogn Neurosci Rev. 2003 Dec;2(4):227-60
– reference: 15022032 - Eur J Clin Pharmacol. 2004 Apr;60(2):103-7
– reference: 18306243 - Ann Neurol. 2008 Mar;63(3):295-302
– reference: 20021728 - Br J Math Stat Psychol. 2010 May;63(Pt 2):379-93
– reference: 12766934 - Hum Psychopharmacol. 2003 Jun;18(4):291-9
– reference: 18164144 - Drug Alcohol Depend. 2008 Apr 1;94(1-3):142-50
– reference: 7862879 - Psychopharmacology (Berl). 1994 Jun;115(1-2):1-8
– reference: 9476695 - Drug Alcohol Depend. 1997 Dec;49(1):17-24
– reference: 21264319 - PLoS One. 2011 Jan 11;6(1):e16088
– reference: 23261866 - Neuropharmacology. 2013 Apr;67:476-84
– reference: 9234049 - Exp Clin Psychopharmacol. 1997 May;5(2):130-6
– reference: 8834422 - J Clin Psychopharmacol. 1996 Feb;16(1):72-6
– reference: 22906516 - Biol Psychiatry. 2013 Feb 1;73(3):219-24
– reference: 1602393 - J Pharmacol Exp Ther. 1992 Jun;261(3):885-94
– reference: 17561238 - Pharmacol Biochem Behav. 2007 Jun-Jul;87(2):289-96
– reference: 21123574 - J Neurosci. 2010 Dec 1;30(48):16284-92
– reference: 22300101 - Future Med Chem. 2012 Feb;4(2):245-65
– reference: 20201847 - Ann N Y Acad Sci. 2010 Feb;1187:76-100
– reference: 16972106 - Psychopharmacology (Berl). 2006 Nov;189(1):17-25
– reference: 2512504 - NIDA Res Monogr. 1989;92:73-100
– reference: 11325419 - Pharmacol Biochem Behav. 2001 Mar;68(3):611-27
– reference: 12325108 - Stat Med. 2002 Oct 15;21(19):2917-30
– reference: 22735770 - Neuropharmacology. 2013 Jan;64:452-63
– reference: 22149529 - Expert Rev Cardiovasc Ther. 2012 Jan;10(1):105-27
– reference: 17981720 - Front Biosci. 2008 Jan 01;13:2391-9
– reference: 3663788 - Biol Psychiatry. 1987 Nov;22(11):1357-68
– reference: 17913879 - Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16311-6
– reference: 24324449 - Front Psychol. 2013 Nov 26;4:863
– reference: 12213517 - Pharmacol Biochem Behav. 2002 Nov;73(4):729-41
– reference: 15582920 - J Psychopharmacol. 2004 Dec;18(4):534-43
– reference: 22654774 - Front Psychiatry. 2012 May 28;3:44
– reference: 2302795 - Clin Chem. 1990 Feb;36(2):391
– reference: 16237380 - Neuropsychopharmacology. 2006 May;31(5):1064-74
– reference: 12927652 - Drug Alcohol Depend. 2003 Aug 20;71(2):143-52
– reference: 20307491 - Biochem Biophys Res Commun. 2010 Apr 16;394(4):988-92
– reference: 21464202 - Nicotine Tob Res. 2011 Jun;13(6):401-11
– reference: 20166094 - Cochrane Database Syst Rev. 2010 Feb 17;(2):CD007380
– reference: 17962524 - Science. 2007 Nov 23;318(5854):1309-12
– reference: 19058926 - Drug Alcohol Depend. 2009 Apr 1;101(1-2):34-41
– reference: 15019424 - Neurosci Biobehav Rev. 2004 Jan;27(8):739-49
– reference: 20182056 - J Alzheimers Dis. 2010;20 Suppl 1:S35-49
– reference: 5554941 - Clin Pharmacol Ther. 1971 Mar-Apr;12(2):245-58
– reference: 21072503 - Psychopharmacology (Berl). 2011 Apr;214(3):665-74
– reference: 10049999 - Pharmacol Rev. 1999 Mar;51(1):83-133
– reference: 11927167 - Neuropsychopharmacology. 2002 Apr;26(4):422-30
– reference: 21731559 - Front Neuroanat. 2011 Jun 17;5:36
– reference: 18428072 - Am J Drug Alcohol Abuse. 2008;34(3):293-305
– reference: 10780285 - Behav Pharmacol. 1999 Dec;10(8):707-16
– reference: 1786488 - Br J Addict. 1991 Dec;86(12):1563-70
– reference: 1595423 - Addict Behav. 1992;17(1):27-33
– reference: 22905331 - J Addict Res Ther. 2012 Mar 28;S1:null
– reference: 9832935 - Behav Pharmacol. 1998 May;9(3):207-17
– reference: 15528409 - Science. 2004 Dec 10;306(5703):1940-3
SSID ssj0000398921
Score 1.8609009
Snippet Due to indirect modulation of dopamine transmission, adenosine receptor antagonists may be useful in either treating cocaine use or improving disrupted...
SourceID unpaywall
pubmedcentral
proquest
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 176
Title Comparison of Caffeine and d-amphetamine in Cocaine-Dependent Subjects: Differential Outcomes on Subjective and Cardiovascular Effects, Reward Learning, and Salivary Paraxanthine
URI https://www.ncbi.nlm.nih.gov/pubmed/25414797
https://www.proquest.com/docview/1826603864
https://pubmed.ncbi.nlm.nih.gov/PMC4235768
https://doi.org/10.4172/2155-6105.1000176
UnpaywallVersion publishedVersion
Volume 5
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 2155-6105
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000398921
  issn: 2155-6105
  databaseCode: KQ8
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1NT9tAEF2VcOBEiyiQiqKtxIlicOzd9dIbMkWISpS2RIKTNWuvATV1UGyL0p_VX8hMvLEIID5ukTNeO5rnnTeeyRvG1v3A5oa6p2SgpYf8NvVAhjuexvQizXxDgwWo2-JIHfTF4ak8dWLR9F-YO_V7gbF1GyOSxPTGl1TOR_SoGTarJNLuDpvtHx3vntHwuIlNU7V8_LzpuPOATD7siZyriyu4uYbB4E7A2X_btGqVY51C6jP5vVVXZiv9d0_F8UW_5R2bd7ST7zY4WWBvbLHI_sftEEI-zHkMeW6RdHIoMp55gH62FfyhI5cFjzHo4Udvz03NrTjuOfQSp_zC99yUFdwtBvx7XSGKbclxVWeCO-p40Xiq-ZU3ysnlJv9pqXeXO63X882x8S-gKtXohh_DCP4iAC7w8u9Zf__rSXzguRkOXorEQXlCCxtlkKoAhMhxS5MIBQzMyPN6xkhtMAOPIO0pPzdaZELmPRAAYYY0L8TkJ1xinWJY2BXGbah9hXRIZBbTLPB1HpA4oTRCWYurd5k_8XCSOoFzmrMxSDDRIQck5ICEHJA4B3TZRnvKVaPu8ZTxpwlsEnwGqbAChR3WZUI5mvJDrfAelhsYtcsFNGc92om6LJoCWGtA-t7T3xSXF2Odb0FSREp32ecWis_f5YdXWa-yTjWq7UckVpVZYzPffug192DdAvFiHFk
linkProvider Unpaywall
linkToUnpaywall http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3BTttAEF1BOPRUWgFtEKCtxAkwdezd9dIbMkWIAyAgEj1Zs_YaEMFBsS2gn9UvZCbeWKRUFG6RM147muedN57JG8bW_cDmhrqnZKClh_w29UCGO57G9CLNfEODBajb4kgd9MXhhbxwYtH0X5hn9XuBsfU7RiSJ6Y0vqZyP6FGzbE5JpN0dNtc_Otn9RcPjJjZN1fLf503HnRdk8mVP5Ie6uIPHexgMngWc_fmmVasc6xRSn8nNdl2Z7fT3XyqOb_otn9hHRzv5boOTz2zGFgvsT9wOIeTDnMeQ5xZJJ4ci45kH6GdbwS0duS54jEEPP3p7bmpuxXHPoZc45Q--56as4G4x4Md1hSi2JcdVnQnuqONF46nmV94oJ5db_NRS7y53Wq-XW2PjM6Aq1eiRn8AIHhAAV3j5Rdbf_3keH3huhoOXInFQntDCRhmkKgAhctzSJEIBAzPyvJ4xUhvMwCNIe8rPjRaZkHkPBECYIc0LMfkJl1inGBb2K-M21L5COiQyi2kW-DoPSJxQGqGsxdW7zJ94OEmdwDnN2RgkmOiQAxJyQEIOSJwDumyjPeWuUfd4zfjbBDYJPoNUWIHCDusyoRxN-aFWeA9fGhi1ywU0Zz3aibosmgJYa0D63tPfFNdXY51vQVJESnfZZgvF_9_l8rusV1inGtV2FYlVZdbcI_UETQcbZA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Comparison+of+Caffeine+and+d-amphetamine+in+Cocaine-Dependent+Subjects%3A+Differential+Outcomes+on+Subjective+and+Cardiovascular+Effects%2C+Reward+Learning%2C+and+Salivary+Paraxanthine&rft.jtitle=Journal+of+addiction+research+%26+therapy&rft.au=Lane%2C+Scott+D&rft.date=2014&rft.issn=2155-6105&rft.eissn=2155-6105&rft.volume=5&rft.issue=2&rft_id=info:doi/10.4172%2F2155-6105.1000176&rft.externalDBID=n%2Fa&rft.externalDocID=10_4172_2155_6105_1000176
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2155-6105&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2155-6105&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2155-6105&client=summon